Kenvue Inc. (NYSE: KVUE) shares surged dramatically in premarket trading on Monday, November 3, 2025, following the announcement that Kimberly-Clark Corporation will acquire the Tylenol maker in a cash and stock transaction valued at approximately $48.7 billion.
The deal represents one of the largest buyouts in the U.S. consumer goods sector to date and would create a massive consumer health and personal care company with roughly $32 billion in combined annual revenues. Kenvue shareholders will receive $21.01 per share, representing a significant 46.2% premium over the stock’s closing price of $14.37 on October 31.
Kimberly-Clark’s Largest Acquisition Yet: Expected Revenue and Earnings Impact
Kimberly-Clark announced on Monday it will acquire Kenvue in a transformative deal that brings together iconic consumer brands under one roof. Under the agreement, Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share held, valuing the transaction at more than $40 billion in equity value.
The merger will unite Kimberly-Clark’s personal care portfolio, including Huggies, Kleenex, and Kotex, with Kenvue’s consumer health brands such as Tylenol, Neutrogena, and Band-Aid, creating a company with 10 billion-dollar brands.
The combined entity is projected to generate approximately $32 billion in annual revenue and $7 billion in adjusted EBITDA based on 2025 projections. Kimberly-Clark expects to realize approximately $2.1 billion in total run-rate synergies, including $1.9 billion in cost synergies and $500 million in revenue synergies, partially offset by $300 million in reinvestments.
The transaction is expected to be accretive to Kimberly-Clark’s adjusted earnings per share by the second year. Upon completion, current Kimberly-Clark shareholders will own approximately 54% of the combined company, with Kenvue shareholders owning the remaining 46%. The acquisition is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.
Kenvue Shares Surge 18% in Premarket Trading on Massive Premium Offer
Kenvue shares jumped to $16.95 in premarket trading at 8:29:59 AM EST on November 3, representing a dramatic 17.91% surge from the previous day’s close of $14.37. The $21.01 per share offer price represents a substantial 46.2% premium, providing significant upside for shareholders who had endured a difficult year.
Prior to the announcement, the stock had been trading near its 52-week low of $14.02, reflecting ongoing challenges including weak retail sales, litigation concerns, and regulatory scrutiny. The company’s year-to-date returns showed a steep decline of 30.78% as of October 31, with one-year returns down 34.98%.
At the previous close, Kenvue had a market capitalization of $27.577 billion and traded at a trailing P/E ratio of 19.16. The company generates annual revenue of $15.14 billion with impressive gross profit margins of 58.15%. Analysts had maintained an average price target of $19.63 before the acquisition announcement, with the stock’s 52-week range spanning from $14.02 to $25.17.
The acquisition represents a strategic exit for Kenvue shareholders following months of struggles, including the departure of its CEO in July and concerns over potential Tylenol litigation related to autism claims made by President Trump, though not backed by scientific evidence.